

Board of Directors: 11.1.18

Agenda Item: Bo.1.18.26

Report from the Partnership Committee

1 December 2017

Presented by:	Professor Bill McCarthy, Chairman	Author:	Fiona Ritchie, Trust Secretary
Previously considered by:	N/A		

Key points	Purpose:
1. This paper provides a brief summary of the key matters that were discussed at the meeting of the Partnerships Committee which was held on 1 December 2017.	To discuss and note

Executive Summary:
The purpose of the Partnerships Committee, as set out in its Terms of Reference, is to provide detailed scrutiny of the Foundation Trust's arrangements for partnerships and collaborative working in order to provide assurance and, if necessary, raise concerns or make recommendations to the Board of Directors.

Financial implications:

Regulatory relevance:

Monitor:	
-----------------	--

Equality Impact / Implications:	Is there likely to be any impact on any of the protected characteristics? (Age, Disability, Gender, Gender Reassignment, Pregnancy and Maternity, Race, Religion or Belief, Sexual Orientation, Health Inequalities, Human Rights) Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> If yes, what is the mitigation against this?
--	--

Other:	
---------------	--

Strategic Objective:	To deliver our financial plan and key performance targets
<i>Reference to Strategic Objective(s) this paper relates to</i>	To provide outstanding care for patients
	To be a continually learning organisation
	To collaborate effectively with local and regional partners

Partnerships Committee – 1 December 2017

1. Introduction

The purpose of this paper is to advise the Board of Directors of the key matters discussed and a brief summary of agenda items of the Committee which was held on 1 December 2017.

2. Key Matters discussed at the meeting held on 1 December 2017

- STP
- WYAAT
- Pathology Joint Venture
- Joint Clinical Strategies
- Bradford

3. Agenda items

3.1 Terms of Reference

As this was the inaugural meeting of the Committee the Terms of Reference of the Committee, which had been agreed by the Board in July 2017, were reviewed and found to remain suitable. The role of the Committee is to give assurance to the Board that the Foundation Trust's work in partnerships is advancing the achievement of our clinical strategy. It will give steers to the Foundation Trust's representatives on partnership bodies; and will raise any concerns about divergence to the Board.

3.2 STP Update

An update was provided on the current state of the West Yorkshire and Harrogate Sustainability and Transformation Partnership and what steps it will take to become an Accountable Care System in the future.

3.3 WYAAT Update

A brief summary was given on the key developments in the WYAAT programme via the WYAAT Programme Director's report. This will become a regular item. The Pathology and Estates & Facilities work streams were discussed in more detail. This item will be further discussed at the Major Projects Committee and future Board of Director Meetings.

3.4 Pathology Joint Venture Update

An update was given on the strategic issues relating to the Pathology Joint Venture with Airedale FT (AHFT).

WYAAT CEOs sent a collective response to NHSI regarding the regulator's proposal to consolidate Pathology Services in 29 centres across England. A further joint letter from BTHFT and AHFT was sent to NHSI. A formal response has not yet been received.

Board of Directors: 11.1.18

Agenda Item: Bo.1.18.26

3.5 Bradford Accountable Care Board/Provider Alliance

The partnerships within Bradford were discussed. BTHFT participates in the development of an accountable care system for Bradford which looks to a model where various providers and commissioners work together to consider agreed service models, share intelligence & support and delivery of services by the most appropriate partner(s).

3.6 EMT (Partnerships) Report

BTHFT Executive has started a new process for monitoring its collaboration projects through an Executive Management Team partnership meeting. This will now formally report into this Committee. Discussion occurred around progress made.

3.7 Stakeholder Management

The stakeholder management programme was launched in September 2017. The progress to date was discussed.

3.8 Board Assurance Framework

The Partnership Committee is responsible for the following strategic risk in the Board Assurance Framework (BAF).

- **SR5: To collaborate effectively with local and regional partners**
The Executive Lead is the Director of Strategy

The Committee discussed, reviewed and amended the risk whilst gaining assurance on the management of the risk.

4. Escalation to the Corporate Risk Register

There were no items to escalate to the Corporate Risk Register.

5. Recommendation

The Board of Directors is asked to note the above points.